Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials

被引：39

作者：

Eichenauer, Dennis A. ^{[1
,2
]}

Becker, Ingrid ^{[3
]}

Monsef, Ina ^{[4
]}

Chadwick, Nicholas ^{[5
]}

de Sanctis, Vitaliana ^{[6
]}

Federico, Massimo ^{[7
]}

Fortpied, Catherine ^{[8
]}

Gianni, Alessandro M. ^{[9
]}

Henry-Amar, Michel ^{[10
]}

Hoskin, Peter ^{[11
]}

Johnson, Peter ^{[12
]}

Luminari, Stefano ^{[7
,15
]}

Bellei, Monica ^{[7
]}

Pulsoni, Alessandro ^{[13
]}

Sydes, Matthew R. ^{[14
]}

Valagussa, Pinuccia ^{[9
]}

Viviani, Simonetta ^{[9
]}

Engert, Andreas ^{[1
,2
]}

Franklin, Jeremy ^{[3
]}

机构：

[1] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany

[2] Univ Hosp Cologne, GHSG, Cologne, Germany

[3] Univ Cologne, Inst Med Stat Informat & Epidemiol, Cologne, Germany

[4] Univ Hosp Cologne, Dept Internal Med 1, Cochrane Haematol Malignancies Grp, Cologne, Germany

[5] UCL, Canc Trials Ctr, London, England

[6] Univ Roma La Sapienza, Dept Radiotherapy, Rome, Italy

[7] Univ Modena & Reggio Emilia, Modena, Italy

[8] EORTC, Brussels, Belgium

[9] Ist Nazl Tumori, Milan, Italy

[10] Ctr Francois Baclesse, Ctr Traitement Donnees Canceropole Nord Ouest, Caen, France

[11] Mt Vernon Canc Ctr, Northwood, Middx, England

[12] Univ Southampton, Canc Res UK Ctr, Southampton, Hants, England

[13] Univ Roma La Sapienza, Cellular Biotechnol & Hematol Dept, Rome, Italy

[14] UCL, Clin Trials Unit, MRC, London, England

[15] Arcispedale S Maria Nuova IRCCS, Hematol, Reggio Emilia, Italy

来源：

HAEMATOLOGICA | 2017年 / 102卷 / 10期

关键词：

INVOLVED-FIELD RADIOTHERAPY; REQUIRING PROLONGED OBSERVATION; 2ND CANCER-RISK; STANFORD-V; INTENSIFIED CHEMOTHERAPY; BRENTUXIMAB VEDOTIN; INTERMEDIATE-STAGE; COMPLETE REMISSION; ADAPTED TREATMENT; COMBINED-MODALITY;

D O I：

10.3324/haematol.2017.167478

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Treatment intensification to maximize disease control and reduced intensity approaches to minimize the risk of late sequelae have been evaluated in newly diagnosed Hodgkin lymphoma. The influence of these interventions on the risk of secondary malignant neoplasms, progression-free survival and overall survival is reported in the meta-analysis herein, based on individual patient data from 9498 patients treated within 16 randomized controlled trials for newly diagnosed Hodgkin lymphoma between 1984 and 2007. Secondary malignant neoplasms were meta-analyzed using Peto's method as time-to-event outcomes. For progression-free and overall survival, hazard ratios derived from each trial using Cox regression were combined by inverse-variance weighting. Five study questions (combined-modality treatment vs. chemotherapy alone; more extended vs. involved-field radiotherapy; radiation at higher doses vs. radiation at 20 Gy; more vs. fewer cycles of the same chemotherapy protocol; standard-dose chemotherapy vs. intensified chemotherapy) were investigated. After a median follow-up of 7.4 years, dose-intensified chemotherapy resulted in better progression-free survival rates (P=0.007) as compared with standard-dose chemotherapy, but was associated with an increased risk of therapy-related acute myeloid leukemia/myelodysplastic syndromes (P=0.0028). No progression-free or overall survival differences were observed between combined-modality treatment and chemotherapy alone, but more secondary malignant neoplasms were seen after combined-modality treatment (P=0.010). For the remaining three study questions, outcomes and secondary malignancy rates did not differ significantly between treatment strategies. The results of this meta-analysis help to weigh up efficacy and secondary malignancy risk for the choice of first-line treatment for Hodgkin lymphoma patients. However, final conclusions regarding secondary solid tumors require longer follow-up.

引用

页码：1748 / 1757

页数：10

共 52 条

[21] ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial [J].

Federico, Massimo ;

Luminari, Stefano ;

Iannitto, Emilio ;

Polimeno, Giuseppe ;

Marcheselli, Luigi ;

Montanini, Antonella ;

La Sala, Antonio ;

Merli, Francesco ;

Stelitano, Caterina ;

Pozzi, Samantha ;

Scalone, Renato ;

Di Renzo, Nicola ;

Musto, Pellegrino ;

Baldini, Luca ;

Cervetti, Giulia ;

Angrilli, Francesco ;

Mazza, Patrizio ;

Brugiatelli, Maura ;

Gobbi, Paolo G. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) :805-811

[22] Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease [J].

Ferme, Christophe ;

Eghbali, Houchingue ;

Meerwaldt, Jacobus H. ;

Rieux, Chantal ;

Bosq, Jacques ;

Berger, Francoise ;

Girinsky, Theodore ;

Brice, Pauline ;

van't Veer, Mars B. ;

Walewski, Jan A. ;

Lederlin, Pierre ;

Tirelli, Umberto ;

Carde, Patrice ;

Van den Neste, Eric ;

Gyan, Emmanuel ;

Monconduit, Mathieu ;

Divine, Marine ;

Raemaekers, John M. M. ;

Salles, Gilles ;

Noordijk, Evert M. ;

Creemers, Geert-Jan ;

Gabarre, Jean ;

Hagenbeek, Anton ;

Reman, Oumedaly ;

Blanc, Michel ;

Thomas, Jose ;

Vie, Brigitte ;

Kluin-Nelemans, Johanna C. ;

Viseu, Fernando ;

Baars, Joke W. ;

Poortmans, Philip ;

Lugtenburg, Pieternella J. ;

Carrie, Christian ;

Jaubert, Jerome ;

Henry-Amar, Michel .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (19) :1916-1927

[23] Second malignancy risk associated with treatment of Hodgkin's lymphoma:: meta-analysis of the randomised trials [J].

Franklin, J. ;

Pluetschow, A. ;

Paus, M. ;

Specht, L. ;

Anselmo, A. -P. ;

Aviles, A. ;

Biti, G. ;

Bogatyreva, T. ;

Bonadonna, G. ;

Brillant, C. ;

Cavalieri, E. ;

Diehl, V. ;

Eghbali, H. ;

Ferme, C. ;

Henry-Amar, M. ;

Hoppe, R. ;

Howard, S. ;

Meyer, R. ;

Niedzwiecki, D. ;

Pavlovsky, S. ;

Radford, J. ;

Raemaekers, J. ;

Ryder, D. ;

Schiller, P. ;

Shakhtarina, S. ;

Valagussa, P. ;

Wilimas, J. ;

Yahalom, J. .

ANNALS OF ONCOLOGY, 2006, 17 (12) :1749-1760

[24] Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk [J].

Franklin, J. G. ;

Paus, M. D. ;

Pluetschow, A. ;

Specht, L. .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2005, (04)

[25]

Gerhartz HH, 1997, P ASCO, V16, p8a

[26] ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: Final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi [J].

Gobbi, PG ;

Levis, A ;

Chisesi, T ;

Broglia, C ;

Vitolo, U ;

Stelitano, C ;

Pavone, V ;

Cavanna, L ;

Santini, G ;

Merli, F ;

Liberati, M ;

Baldini, L ;

Deliliers, GL ;

Angelucci, E ;

Bordonaro, R ;

Federico, M .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) :9198-9207

[27] Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496) [J].

Gordon, Leo I. ;

Hong, Fangxin ;

Fisher, Richard I. ;

Bartlett, Nancy L. ;

Connors, Joseph M. ;

Gascoyne, Randy D. ;

Wagner, Henry ;

Stiff, Patrick J. ;

Cheson, Bruce D. ;

Gospodarowicz, Mary ;

Advani, Ranjana ;

Kahl, Brad S. ;

Friedberg, Jonathan W. ;

Blum, Kristie A. ;

Habermann, Thomas M. ;

Tuscano, Joseph M. ;

Hoppe, Richard T. ;

Horning, Sandra J. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06) :684-691

[28] Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma [J].

Herbst, Christine ;

Rehan, Fareed Ahmed ;

Skoetz, Nicole ;

Bohlius, Julia ;

Brillant, Corinne ;

Schulz, Holger ;

Monsef, Ina ;

Specht, Lena ;

Engert, Andreas .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (02)

[29] CONVINCING EVIDENCE FROM CONTROLLED AND UNCONTROLLED STUDIES ON THE LIPID-LOWERING EFFECT OF A STATIN [J].

Higgins, Julian .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (12)

[30] Randomized Comparison of the Stanford V Regimen and ABVD in the Treatment of Advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244 [J].

Hoskin, Peter J. ;

Lowry, Lisa ;

Horwich, Alan ;

Jack, Andrew ;

Mead, Ben ;

Hancock, Barry W. ;

Smith, Paul ;

Qian, Wendi ;

Patrick, Philippa ;

Popova, Bilyana ;

Pettitt, Andrew ;

Cunningham, David ;

Pettengell, Ruth ;

Sweetenham, John ;

Linch, David ;

Johnson, Peter W. M. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (32) :5390-5396

← 1 2 3 4 5 6 →